Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
KraneShares MSCI All China Health Care Index ETF
(NY:
KURE
)
19.03
-0.08 (-0.42%)
Official Closing Price
Updated: 8:00 PM EDT, Jul 25, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about KraneShares MSCI All China Health Care Index ETF
Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains'
July 16, 2025
Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk.
Via
Benzinga
Topics
Government
World Trade
Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies
July 11, 2025
Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest.
Via
Benzinga
Topics
Government
World Trade
Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare'
June 20, 2025
A debate over the healthcare system erupted on X, pitting Mark Cuban against Elizabeth Warren over the root causes of soaring drug prices.
Via
Benzinga
China Stocks Look Set For A Rebound, Morgan Stanley Quant Strategists Say
September 13, 2022
Investors in mainland China are rapidly unwinding their stock-index hedges, in an indication that a possible end to Chengdu’s lockdown and policies to stabilize the yuan will lead to a near-term market...
Via
Benzinga
Trump's Drug Price Order Hits PBMs Hardest: CVS, Cigna, UNH In Focus As Experts Highlight 'Racket,' Pricing Distortion
May 19, 2025
Trump signed an executive order to lower drug prices, which could hit pharmacy benefit managers (PBMs) hard. PBMs have come under scrutiny for opaque pricing practices. Mark Cuban calls PBMs a racket.
Via
Benzinga
Topics
Government
3 ETFs Thriving in April’s Market Chaos—Are You Missing Out?
April 15, 2025
These ETFs beat the S&P 500 in April 2025’s turbulent market. Learn how TOLZ, VIXY, and KURE can help stabilize your investment strategy.
Via
MarketBeat
Topics
ETFs
Economy
Stocks
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies
April 11, 2025
Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs.
Via
Benzinga
Topics
Government
World Trade
China's Market Rebound: Is The NPC Meeting A Turning Point For Investors?
March 07, 2025
China's NPC meeting has sparked optimism in the market, with Chinese stocks and bonds rallying. Investors are hopeful for growth targets but remain skeptical.
Via
Benzinga
Topics
Bonds
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.